Clinical Trial: Phase I Study of Cosibelimab and Balixafortide in Metastatic Pancreatic Ductal Adenocarcinoma

U.S., May 22 -- ClinicalTrials.gov registry received information related to the study (NCT06981806) titled 'Phase I Study of Cosibelimab and Balixafortide in Metastatic Pancreatic Ductal Adenocarcinoma' on May 13.

Brief Summary: This is a single-center, open-label, phase 1 dose escalation and dose expansion (safety confirmation) trial to evaluate the safety and tolerability of balixafortide and cosibelimab in patients with metastatic PDAC who progressed after SOC chemotherapy.

Study Start Date: July, 2025

Study Type: INTERVENTIONAL

Condition: Metastatic Pancreatic Ductal Adenocarcinoma

Intervention: DRUG: Balixafortide

Dose: 7.5 mg/kg Route: IV (2hr) Frequency: Weekly

DRUG: Balixafortide

Dose: 11 mg/kg Route: IV (2hr) Frequency: W...